Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.61 Million CHF | 13.69% |
| 2022 | 1.42 Million CHF | -51.22% |
| 2021 | 2.91 Million CHF | -19.28% |
| 2020 | 3.61 Million CHF | 30.77% |
| 2019 | 2.76 Million CHF | -54.29% |
| 2018 | 6.04 Million CHF | 1109.03% |
| 2017 | 499.89 Thousand CHF | 2784.73% |
| 2016 | 17.32 Thousand CHF | -57.0% |
| 2015 | 40.3 Thousand CHF | -52.81% |
| 2014 | 85.4 Thousand CHF | -6.93% |
| 2013 | 91.76 Thousand CHF | -24.22% |
| 2012 | 121.08 Thousand CHF | -95.71% |
| 2011 | 2.82 Million CHF | 42.94% |
| 2010 | 1.97 Million CHF | -51.71% |
| 2009 | 4.09 Million CHF | -84.74% |
| 2008 | 26.8 Million CHF | 5405.28% |
| 2007 | 486.93 Thousand CHF | -89.72% |
| 2006 | 4.73 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 234.91 Thousand CHF | 27.79% |
| 2024 Q2 | 115.27 Thousand CHF | -50.93% |
| 2023 FY | 1.61 Million CHF | 13.69% |
| 2023 Q4 | 183.82 Thousand CHF | -43.91% |
| 2023 Q3 | 327.73 Thousand CHF | -48.05% |
| 2023 Q2 | 630.87 Thousand CHF | 25.95% |
| 2023 Q1 | 500.89 Thousand CHF | -15.45% |
| 2022 Q1 | 237.23 Thousand CHF | -40.32% |
| 2022 Q3 | 409.41 Thousand CHF | 123.29% |
| 2022 FY | 1.42 Million CHF | -51.22% |
| 2022 Q2 | 183.35 Thousand CHF | -22.71% |
| 2022 Q4 | 592.43 Thousand CHF | 44.7% |
| 2021 Q1 | 844.22 Thousand CHF | -53.63% |
| 2021 FY | 2.91 Million CHF | -19.28% |
| 2021 Q2 | 992.59 Thousand CHF | 17.57% |
| 2021 Q3 | 682 Thousand CHF | -31.29% |
| 2021 Q4 | 397.48 Thousand CHF | -41.72% |
| 2020 FY | 3.61 Million CHF | 30.77% |
| 2020 Q4 | 1.82 Million CHF | 6578.04% |
| 2020 Q3 | 27.26 Thousand CHF | -96.83% |
| 2020 Q2 | 860.79 Thousand CHF | -4.79% |
| 2020 Q1 | 904.06 Thousand CHF | -13.09% |
| 2019 Q3 | 502.35 Thousand CHF | -3.29% |
| 2019 Q1 | 700.86 Thousand CHF | 4.98% |
| 2019 FY | 2.76 Million CHF | -54.29% |
| 2019 Q4 | 1.04 Million CHF | 107.06% |
| 2019 Q2 | 519.43 Thousand CHF | -25.89% |
| 2018 FY | 6.04 Million CHF | 1109.03% |
| 2018 Q3 | 667.61 Thousand CHF | -75.12% |
| 2018 Q2 | 2.68 Million CHF | 0.0% |
| 2018 Q1 | 2.68 Million CHF | 1865.16% |
| 2018 Q4 | 667.61 Thousand CHF | -0.0% |
| 2017 Q3 | 136.56 Thousand CHF | 20.45% |
| 2017 FY | 499.89 Thousand CHF | 2784.73% |
| 2017 Q4 | 136.56 Thousand CHF | 0.0% |
| 2017 Q2 | 113.38 Thousand CHF | 0.0% |
| 2017 Q1 | 113.38 Thousand CHF | 76.81% |
| 2016 Q1 | 141.74 Thousand CHF | -59.61% |
| 2016 FY | 17.32 Thousand CHF | -57.0% |
| 2016 Q4 | 64.12 Thousand CHF | 0.0% |
| 2016 Q3 | 64.12 Thousand CHF | -54.76% |
| 2016 Q2 | 141.74 Thousand CHF | 0.0% |
| 2015 Q4 | 350.91 Thousand CHF | 0.0% |
| 2015 Q2 | 44.75 Thousand CHF | -0.0% |
| 2015 Q1 | 44.75 Thousand CHF | -70.92% |
| 2015 FY | 40.3 Thousand CHF | -52.81% |
| 2015 Q3 | 350.91 Thousand CHF | 684.16% |
| 2014 Q1 | - CHF | -100.0% |
| 2014 Q4 | 153.89 Thousand CHF | 0.0% |
| 2014 Q3 | 153.89 Thousand CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 FY | 85.4 Thousand CHF | -6.93% |
| 2013 Q3 | 1.37 Million CHF | 1830.17% |
| 2013 Q4 | 1.37 Million CHF | 0.0% |
| 2013 FY | 91.76 Thousand CHF | -24.22% |
| 2013 Q1 | 71.04 Thousand CHF | 0.0% |
| 2013 Q2 | 71.04 Thousand CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2012 FY | 121.08 Thousand CHF | -95.71% |
| 2012 Q4 | - CHF | 0.0% |
| 2011 FY | 2.82 Million CHF | 42.94% |
| 2010 FY | 1.97 Million CHF | -51.71% |
| 2009 FY | 4.09 Million CHF | -84.74% |
| 2008 FY | 26.8 Million CHF | 5405.28% |
| 2007 FY | 486.93 Thousand CHF | -89.72% |
| 2006 FY | 4.73 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BB Biotech AG | -199.56 Million CHF | 100.81% |
| Basilea Pharmaceutica AG | 157.63 Million CHF | 98.974% |
| Evolva Holding SA | 9.43 Million CHF | 82.865% |
| Idorsia Ltd | 152.38 Million CHF | 98.939% |
| Kuros Biosciences AG | 33.56 Million CHF | 95.182% |
| Molecular Partners AG | 7.03 Million CHF | 77.022% |
| Relief Therapeutics Holding AG | 6.03 Million CHF | 73.194% |
| Santhera Pharmaceuticals Holding AG | 103.41 Million CHF | 98.436% |